Compare · HKPD vs MCK
HKPD vs MCK
Side-by-side comparison of Cellyan Biotechnology Co. Ltd (HKPD) and McKesson Corporation (MCK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HKPD and MCK operate in Other Pharmaceuticals (Health Care), so they compete in similar markets.
- MCK is the larger of the two at $101.08B, about 6696.6x HKPD ($15.1M).
- Over the past year, HKPD is down 72.7% and MCK is up 19.2% - MCK leads by 91.9 points.
- MCK has been more active in the news (13 items in the past 4 weeks vs 2 for HKPD).
- MCK has more recent analyst coverage (25 ratings vs 0 for HKPD).
- Company
- Cellyan Biotechnology Co. Ltd
- McKesson Corporation
- Price
- $0.35-2.64%
- $841.14+1.99%
- Market cap
- $15.1M
- $101.08B
- 1M return
- -5.79%
- +9.73%
- 1Y return
- -72.66%
- +19.21%
- Industry
- Other Pharmaceuticals
- Other Pharmaceuticals
- Exchange
- NASDAQ
- NYSE
- IPO
- 2025
- News (4w)
- 2
- 13
- Recent ratings
- 0
- 25
McKesson Corporation
McKesson Corporation provides healthcare supply chain management, retail pharmacy, community oncology and specialty care, and healthcare information solutions in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The International segment offers distribution and services to wholesale, institutional, and retail customers in 13 European countries and Canada. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers. The RxTS segment offers CoverMyMeds solution to help patients get the medications; RelayHealth, a workflow solution; RxCrossroads solution for therapies and interventions to biopharma manufacturers; and McKesson Prescription Automation, a customized pharmacy automation technology; and Multi-Client Central Fill as a Service, a pharmacy. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.
Latest HKPD
- SEC Form 6-K filed by Cellyan Biotechnology Co. Ltd
- Cellyan Biotechnology Co., Ltd Receives Nasdaq Notice of Additional Compliance Grace Period
- SEC Form EFFECT filed by Cellyan Biotechnology Co. Ltd
- SEC Form F-3 filed by Cellyan Biotechnology Co. Ltd
- SEC Form 3 filed by new insider Chan Kam Leung
- New insider Wong Lap Sun claimed ownership of 18,468 units of Class A Ordinary Shares (SEC Form 3)
- SEC Form 3 filed by new insider Wang Zifeng
- SEC Form 3 filed by new insider Liu Shu
- SEC Form 3 filed by new insider Zhou Mike Yao
- SEC Form 3 filed by new insider Wu Jingyan
Latest MCK
- McKesson Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SEC Form 4 filed by Director Hinton James H.
- SEC Form 4 filed by Director Doughtie Lynne M
- Director Wilson-Thompson Kathleen was granted 277 shares, increasing direct ownership by 92% to 578 units (SEC Form 4)
- SEC Form 4 filed by Director Dunbar Webster Roy
- Director Caruso Dominic J was granted 277 shares, increasing direct ownership by 43% to 927 units (SEC Form 4)
- SEC Form 4 filed by Director Gerberding Julie L.
- SEC Form 4 filed by Director Lerman Bradley E
- Director Martinez Maria was granted 277 shares, increasing direct ownership by 92% to 578 units (SEC Form 4)
- SEC Form 4 filed by Director Ozan Kevin M